Oramed Pharmaceuticals (FRA:OJU1) Beta: 0.7001 (As of Jul. 03, 2026)


FRA:OJU1 Oramed Pharmaceuticals Inc FRA:OJU1
34 GF Score
Price €3.99
! 5 Warning Signs
View Full Analysis

What is Oramed Pharmaceuticals Beta?

Oramed Pharmaceuticals FRA:OJU1 -4.09% 34 Beta is 0.7001 as of Jul. 03, 2026. GuruFocus rates FRA:OJU1 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-03), Oramed Pharmaceuticals's Beta is 0.7001.


Oramed Pharmaceuticals  (FRA:OJU1) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Oramed Pharmaceuticals Beta Related Terms


Oramed Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Oramed Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oramed Pharmaceuticals Beta Chart

Oramed Pharmaceuticals Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.46 2.75 0.53 -0.13 -2.76

Oramed Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 -1.06 -2.53 -2.76 -1.23

FRA:OJU1 vs EQ, HUMA, NBP: Beta Comparison

For the Biotechnology subindustry, Oramed Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Beta falls into.


FRA:OJU1
34GF Score
Oramed Pharmaceuticals Inc FRA:OJU1
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oramed Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7001 mean?
Oramed Pharmaceuticals (FRA:OJU1) has a Beta of 0.7001 as of Jul. 03, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Oramed Pharmaceuticals and its competitors.
Is Oramed Pharmaceuticals' Beta too high?
Oramed Pharmaceuticals' current Beta is 0.7001. Overall, Oramed Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' Beta compare to EQ and HUMA?
Oramed Pharmaceuticals' Beta of 0.7001 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current Beta is 0.7001. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (FRA:OJU1) has a current Beta of 0.7001. The current Beta is 0.7001. Oramed Pharmaceuticals' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Oramed Pharmaceuticals (FRA:OJU1), the current Beta is 0.7001 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oramed Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
34GF Score

Get the complete analysis for FRA:OJU1

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price